Related Experiment Video

Updated: Jun 16, 2026

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

Topical Janus Kinase Inhibitors for Pediatric Atopic Dermatitis: A Systematic Review of Efficacy and Safety

Aditi Chokshi1, Jennifer Keelin2, Valerie Foy3

  • 1Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA.

Pediatric Dermatology
|June 14, 2026
PubMed

Insights

Topical janus kinase (JAK) inhibitors offer effective, well-tolerated nonsteroidal treatment for pediatric atopic dermatitis (AD). These therapies provide rapid symptom relief and disease control, expanding options for children.

Area of Science:

  • Dermatology
  • Pediatrics
  • Pharmacology

Background:

  • Atopic dermatitis (AD) is a prevalent inflammatory skin condition in children, often managed with topical therapies facing safety and tolerability challenges.
  • Topical janus kinase (JAK) inhibitors represent a novel class of nonsteroidal treatments for AD.
  • Recent pediatric approval of ruxolitinib broadens therapeutic avenues for managing childhood AD.

Purpose of the Study:

  • To systematically review pediatric-exclusive evidence on topical JAK inhibitors for atopic dermatitis.
  • To evaluate the efficacy, safety, and optimal treatment strategies for these agents in pediatric patients.
  • To synthesize current data to inform clinical practice guidelines.

Main Methods:

  • A PRISMA-guided systematic review was performed, searching major databases (PubMed, Embase, Web of Science) and ClinicalTrials.gov.
  • Inclusion criteria focused on studies involving pediatric patients treated with topical JAK inhibitors.
  • Eight studies, including 541 pediatric patients treated with ruxolitinib or delgocitinib, met the criteria.

Main Results:

  • Both ruxolitinib and delgocitinib demonstrated rapid and clinically significant improvements in AD severity and pruritus within weeks.
  • Ruxolitinib showed consistent efficacy across limited and extensive disease, while delgocitinib provided sustained control with continuous use, including in infants.
  • Topical JAK inhibitors were well-tolerated, with adverse event profiles comparable to vehicle and minimal treatment discontinuations; no serious treatment-related adverse events were reported.

Conclusions:

  • Pediatric data indicate that topical JAK inhibitors are effective and safe nonsteroidal options for atopic dermatitis.
  • These agents offer rapid relief of symptoms and sustained disease control.
  • Topical JAK inhibitors represent a valuable addition to steroid-sparing treatment strategies for pediatric AD.
Abstract

Keywords:
atopic dermatitisdelgocitinibjanus kinase inhibitorpediatricruxolitinib

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Acne Infection01:27

Acne Infection

Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...